SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

AbbVie announces positive Phase 3 CERVINO topline for etentamig

AbbVie said its Phase 3 CERVINO trial for investigational etentamig in relapsed/refractory multiple myeloma met both primary endpoints, with etentamig achieving higher objective response results in topline findings.

ABBV

AbbVie on Thursday said topline results from the Phase 3 CERVINO trial of investigational etentamig in patients with relapsed/refractory multiple myeloma were positive. The study met both primary endpoints, with etentamig posting a significantly higher objective response rate and a significantly longer duration of response.

Related stories